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Early  life stress  (ELS)  is a known  risk  factor  for suffering  psychopathology  in  adulthood.  The
hypothalamic–pituitary–adrenal  (HPA)  axis  has  been  described  to be deregulated  in  both  individuals
who  experienced  early  psychosocial  stress  and  in patients  with  a wide  range  of  psychiatric  disorders.
The  NR3C1  gene  codes  for the  glucocorticoid  receptor,  a key  element  involved  in  several  steps  of HPA  axis
modulation.  In this review,  we  gather  existing  evidence  linking  NR3C1  methylation  pattern  with  either
ELS  or psychopathology.  We summarize  that  several  types  of  ELS  have  been  frequently  associated  with
NR3C1  hypermethylation  whereas  hypomethylation  has  been  continuously  found  to  be associated  withR3C1 gene
lucocorticoid receptor
arly life stress
tress-related disorders
post-traumatic  stress  disorder.  In  light  of the  reported  ﬁndings,  the  main  concerns  of ongoing research  in
this ﬁeld  are the  lack  of methodological  consensus  and  selection  of  CpG  sites.  Further  studies  should  target
individual  CpG  site  methylation  assessment  focusing  in  biologically  relevant  areas  such  as  transcription
factor  binding  regions  whereas  widening  the examined  sequence  in  order  to include  all  non-coding  ﬁrst
exons  of the  NR3C1  gene  in  the  analysis.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
Mental disorders affect around one third of Europe’s popula-
ion and cause the greatest effect in terms of disability-adjusted
ife-years (DALYs) (Kaplan and Laing, 2004). Anxious-depressive
isorders have particularly high prevalence ratios as well as the
ighest associated risk of suicide (for a review, see Miret et al.,
013). The lifetime prevalence of major depression disorders
MDD) ranges from 1% to 29.9% depending on biological, geograph-
cal and sociocultural variables (Kessler and Bromet, 2013; Kessler
t al., 2012). The lifetime prevalence for anxiety disorders is around
0% and its lifetime morbid risk is estimated to be as much as 41.7%
n the US (Kessler et al., 2012).
In contrast, although post-traumatic stress disorder (PTSD) has
 moderately low prevalence in developed countries (around 1%),
ts incidence increases dramatically in subjects exposed to a num-
er of severe traumatic experiences (for a review, see Keane et al.,
006). Indeed, PTSD patients must have experienced recent severe
rauma in order to meet the recent DSM5 criteria (American
sychiatric Association, 2013). Finally, borderline personality dis-
rder (BPD) affects 0.5–5% of the general population; many authors
ave reported its association with childhood maltreatment, espe-
ially sexual abuse (Leichsenring et al., 2011).
Epidemiological studies have reported that psychosocially
tressful events are a necessary triggering factor for the adult onset
f an extremely high percentage of the aforementioned mental dis-
rders, which can be referred as “stress-related disorders” (for a
eview, see Slavich et al., 2010). Of particular interest is the exten-
ive scientiﬁc literature on the major causal role of early adversity
n the sensitization to adult psychopathology, with special empha-
is on the impact of childhood maltreatment on vulnerability to
tress-related disorders in adulthood (for reviews of this topic, see
arr et al., 2013; Strüber et al., 2014; Teicher et al., 2003).
Childhood maltreatment prevalence ratios are estimated to be
s high as anything from 4% right up to 16% in developed countries,
epending on the type of abuse (Gilbert et al., 2009); it thus con-
titutes a major health concern in developed societies.
The long latency between early exposure to environmental risk
actors and the late onset of a pathological status is widely observed
n several complex disorders such as cancer, metabolic diseases and
sychiatric conditions. Early life events, such as prenatal stress or
hildhood adversity, have the potential to modify later vulnerabil-
ty to complex disorders due to developmental plasticity, i.e., the
bility to develop in various ways depending on the early environ-
ent allows organisms to adapt. This evolutionary competence is
robably mediated at least in part by epigenetic mechanisms such
s histone modiﬁcations and DNA methylation (Gluckman et al.,
008; Petronis, 2010; Ptak and Petronis, 2010).
The hippocampus is a brain area that is crucial in the modulation
f the hypothalamic–pituitary–adrenal (HPA) axis: our primary
2013). Brieﬂy, upon exposure to stress, the paraventricular nucleus
of the hypothalamus activates and secretes corticotropin-releasing
hormone (CRH) which promotes the release of adrenocorticotropic
hormone (ACTH) from the anterior pituitary to the adrenal glands,
which ﬁnally release glucocorticoids. In humans, cortisol dis-
tributes systemically and executes a wide range of functions
involving the immune, digestive and endocrine systems, including
HPA axis self-regulation. As a lipophilic molecule, cortisol crosses
the cellular membrane by passive diffusion and binds to the cyto-
plasmic mineralocorticoid receptor (MR) and the glucocorticoid
receptor (GR). MR  has a higher afﬁnity for glucocorticoids than GR;
thus, GR activation is key for an individual to appropriately cope
with stress.
Once bound to cortisol, GR can translocate to the nucleus, where
it acts both as a transcription factor and as a repressor. This coupling
enables the dissociation of a chaperone complex, which is preven-
ting nuclear translocation of GR in the absence of glucocorticoids.
Interestingly, both epigenetic modiﬁcations and genetic variability
of a certain co-chaperone of this complex, FKBP5, have been associ-
ated with stress-related disorders, speciﬁcally PTSD (Binder, 2009;
Klengel et al., 2013).
The human glucocorticoid receptor is encoded by the NR3C1
gene, spanning almost one half mega base pairs of chromosome
5. It contains 17 exons, nine of them are non-coding exons located
at the gene promoter (Fig. 1). Seven of these non-coding exons are
clustered along the same CpG island (see Fig. 2 for the complete
sequence).
A decade ago, Weaver et al. (2004) successfully found in rodents
an epigenetic modiﬁcation of the NR3C1 gene that was indica-
tive of differential maternal rearing behavior. Speciﬁcally, rat pups
raised by mothers that exhibited more nursing behavior exhibited
remarkable hypomethylation at a speciﬁc CpG site located at an
NGFI-A binding site; which suggested it was  involved in transcrip-
tion modulation.
Based on prior evidence from animal studies, over the last
decade, a signiﬁcant number of authors have focused their research
on the epigenetic modulation of the NR3C1 gene in humans in asso-
ciation with early stress, as well as with additional variables such as
stress reactivity and different psychopathological conditions. DNA
methylation has been explored in a myriad of tissues and clinical
proﬁles, including both peripheral tissues (blood and saliva) and
central nervous system samples from patients as well as controls.
Nevertheless, many concerns regarding particular epigenetic
modiﬁcations of the NR3C1 gene, the relevance and nature of early
stressors and the speciﬁc clinical proﬁle associated with these vari-
ables, remain to be elucidated.
Within this framework, the main goals of this review are: (i)
to ascertain which methodology should be used to assess DNA
methylation in the NR3C1 gene; (ii) to determine which CpG sites
within the NR3C1 gene are deﬁnitely relevant for the etiology oftress response system. Alterations in both hippocampal volume
nd functionality have been associated with psychiatric disorders,
specially with major depression (Anacker et al., 2011). Indeed,
renatal and childhood trauma can modulate the HPA axis (Ehlert,stress-related disorders, according to published data; and (iii) to
discuss the rationale driving current research on this topic in order
to address future analysis of subjects suffering from stress-related
disorders.
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Fig. 1. NR3C1 gene structure. The NR3C1 gene consists of eight coding exons numbered 2–9 and nine non-coding ﬁrst exons referred to as A–J (excluding “G”) which are
thought to act as alternate promoters. Exons 1D, 1J, 1E, 1B, 1F, 1C and 1H are located within a CpG island spanning 3 kb along the proximal promoter region of NR3C1 gene.
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. Methodology
.1. Selection criteria
Research was conducted via a systematic literature search in the
ubMed, PsycINFO and Web  of Science databases. The search terms
ere the following: “NR3C1 or glucocorticoid receptor”, “methyl-
tion” and “stress or childhood adversity or childhood abuse or
aternal disorder”. The English language ﬁlter was activated, which
xcluded 3 of the 103 papers that the deﬁned search retrieved.
e then excluded from the resulting pool: all papers reporting
esearch on animals (n = 37); and papers which did not report orig-
nal research (n = 30). To be considered suitable for the present
ig. 2. Extended sequence of the CpG island chr5:142,782,071–142,785,071 located in 
apital letters. CpG dinucleotides studied in any of the papers reviewed herein are display
umbering systems are included in order to adjust to previous research: (a) 1–45 referrin
ark  orange), 1E (colored in purple) and 1B (colored in blue), due to their proximity; (c) 1
n  light orange); and (e) 1–76 including the region1H (colored in brown). Negative nume
llumina BeadChip which were not included in the analysis performed by the other autho
2005)  and Presul et al. (2007). Parenthetical numbering is of gene locations with respect
egions. Red has been used to mark 1F CpG #37, as it is the most widely reported in the lid at three different times. CpG dinucleotides with differential methylation may  be
G island described in this gene, which is located at a promoter region.
review, the papers needed to include either an early or a late stress
measure in association with a thorough methylation assessment of
a CpG island located at the NR3C1 gene promoter (Figs. 1 and 2).
The ﬁnal set consisted of 23 papers to be reviewed (Table 1).
2.2. Brief introduction to the assessment instruments and scales
for measuring psychopathology and experienced adversity
Psychiatric diagnoses need to rely on instruments and scales
that measure symptoms, since there is no known biomarker for
any mental disorder. The Diagnostic and Statistical Manual of Men-
tal Disorders (DSM) contains the reference criteria for diagnosing
psychiatric conditions and it is widely used in both health care and
the 5′ untranslated region of the NR3C1 gene. CpG dinucleotides are displayed in
ed in bold. CpG numeration is according to the papers reviewed. Five independent
g to the region 1D (colored in green); (b) 1–46 covering the regions 1J (colored in
–47 as placed in region 1F (colored in red); (d) 1–59 located in region 1C (colored
ration in three individual CpG sites corresponds with dinucleotides assayed in the
rs. Underlined sequences correspond to exons as annotated by Turner and Muller
 to the translation start site within exon 2. Dashed boxes delineate NGFI-A binding
terature, in both animal and human studies.
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Table 1
Summary of studies analyzing NR3C1 methylation as associated to both psychosocial stress and psychopathological condition.
Study Sample
size/characterization
Tissue Analyzed CpG
sites
Methylation
assessment
Expression Stress measure Epigenetic ﬁndings Extent of the
reported
methylation
differences
Correlated
biomarkers
(i.a., cortisol
measurements)
Oberlander
et al. (2008)
n = 82
mother-child
dyads
33 depressed
and treated
mothers
13 depressed
and not treated
mothers
36 controls
Cord blood Exon 1F (and
partial
promoter 1F)
13 CpG sites
analyzed
Pyrosequencing No Prenatal stress
(mood disorder
during
pregnancy) and
infant stress
challenge
Maternal depression
severity was associated
with neonatal 1F
promoter methylation.
<5% CpG speciﬁc
methylation
predicted HPA
reactivity
McGowan et al.
(2009)
n = 36 deceased
donors
12 suicide
victims with
history of
childhood abuse
12 suicide
victims without
history of
childhood abuse
12 controls
without history
of childhood
abuse
Brain
(hippocampus)
Promoter 1F
38 CpG sites
analyzed
Sodium
bisulﬁte
mapping,
cloning and
Sanger
sequencing
Yes Childhood
adversity
(CECA adapted
for
psychological
autopsies)
History of childhood
abuse was associated
with higher
methylation at the
promoter 1F.
Total GR mRNA
expression was
decreased in abused
suicide victims.
<20%
>30% (in CpG
32)
–
Radtke et al.
(2011)
n = 25
mother-child
dyads
8 women
suffered IPV
during
pregnancy
Peripheral
blood (whole
blood)
Promoter 1F
10 CpG sites
analyzed
Sodium
bisulﬁte
mapping,
cloning and
Sanger
sequencing
No Prenatal stress
(mother’s
exposure to
intimate
partner
violence)
The presence of
methylated residues at
promoter 1F was
associated with
maternal exposure to
IPV during pregnancy.
<5% –
Perroud et al.
(2011)
n = 215
101 BPD
subjects
99 MDD subjects
without
past/current
PTSD
15 MDD subjects
with
past/current
PTSD
Peripheral
blood
(leukocytes)
Exon 1F
8 CpG sites
analyzed
Pyrosequencing No Childhood
adversity (CTQ)
Exon 1F methylation
correlated with abuse
severity and number of
maltreatment types.
<5% –
De Rooij et al.
(2012)
n = 675 healthy
subjects
Peripheral
blood (whole
blood)
Exon 1C
amplicon
included 30
CpG sites
Methylation
sensitive PCR
assay
No Stress
reactivity
(psychological
stress protocol)
An adverse lifestyle
was  associated with
lower methylation of
GR  1C promoter.
NA
Mean
methylation
range = 0.064
Lower
methylation
was associated
with decreased
stress
reactivity
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Table 1 (Continued )
Study Sample
size/characterization
Tissue Analyzed CpG
sites
Methylation
assessment
Expression Stress measure Epigenetic ﬁndings Extent of the
reported
methylation
differences
Correlated
biomarkers
(i.a., cortisol
measurements)
Tyrka et al.
(2012)
n = 99 healthy
subjects
Peripheral
blood (whole
blood)
Exon 1F (and
partial
promoter 1F)
13 CpG sites
analyzed
Pyrosequencing No Childhood
adversity (CTQ,
Childhood
Parental Loss
and Parental
Bonding Index)
Childhood adversity
was  associated with
promoter 1F
methylation.
<5% CpG speciﬁc
methylation
was negatively
associated with
cortisol
response after
Dex/CRH test
Labonté et al.
(2012)
n = 56 deceased
donors
21 suicide
victims with
history of
childhood abuse
21 suicide
victims without
history of
childhood abuse
14 controls
Brain
(hippocampus)
Promoters 1B,
1C and 1H
43 CpG sites
analyzed
Pyrosequencing Yes Childhood
adversity
(CECA adapted
for
psychological
autopsies)
Relative expression
levels of total GR, GR1B,
GR1C and GR1H were
decreased in abused
suicides.
Methylation at speciﬁc
CpG sites of 1B and 1C
promoters negatively
correlated with
expression.
1B and 1C speciﬁc CpG
site methylation was
associated with suicide
completion and history
of childhood abuse.
1H promoter showed
hypomethylation in
abused suicides.
<5% –
Mulligan et al.
(2012)
n = 25 mother-
newborn dyads
Sample native to
Democratic
Republic of
Congo (common
exposure to war
and violence
against women)
Cord blood Promoter 1F
39 CpG sites
analyzed
Sodium
bisulﬁte
mapping,
cloning and
sequencing
No Prenatal stress
(maternal
exposure to
war during
pregnancy)
Mother’s exposure to
stress during
pregnancy correlated
with newborn
methylation at
promoter 1F,  which
inversely correlated to
birth weight.
NA –
Edelman et al.
(2012)
n = 92 healthy
subjects
50% female
Saliva Promoter 1F
39 CpG sites
analyzed
Pyrosequencing No Stress
reactivity
(TSST)
Women  showed
greater methylation at
promoter 1F than men.
<5% 1F methylation
was correlated
to stress
reactivity in
women
Melas et al.
(2013)
n = 176 women
93 depressed
83 controls
Saliva Promoter and
exon 1F
47 CpG sites
analyzed
Sequenom
EpiTYPER
platform
(MALDI-TOF
mass
spectrometry)
No Childhood
adversity
(childhood
parental loss)
EPD was associated
with 1F CpG-speciﬁc
hypermethylation.
<10% –
Hompes et al.
(2013)
n = 83
mother-child
dyads
Cord blood Promoters 1D,
1B and 1F
94 CpG sites
analyzed
Sequenom
EpiTYPER
platform
(MALDI-TOF
mass
spectrometry)
No Prenatal stress
(mood disorder
during
pregnancy)
PRAQ scores were
correlated to 1D and 1F
methylation.
NA –
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Hogg et al.
(2013)
n = 161
mother-child
dyads
19 early onset
pre-eclampsia
18 late onset
pre-eclampsia
13
normotensive
intrauterine
growth
restriction
111 controls
Placenta 37 CpG sites
distributed all
across
alternate
non-coding
NR3C1 exons
Illumina 450K
Methylation
BeadChip plus
additional
pyrosequenc-
ing for further
verifying array
ﬁndings
Yes Prenatal stress
(diagnosis of
pre-eclampsia)
1D CpG-speciﬁc
hypermethylation was
found in pre-eclampsia
placentae.
The expression of
NR3C1 mRNA was not
altered in
pre-eclampsia cases.
Glucocorticoid
signaling and
steroidogenic pathway
genes are differentially
methylated in
pre-eclampsia.
<10% –
Conradt et al.
(2013)
n = 482
mother-child
dyads
27 depressed
mothers
18 anxious
mothers
39 mothers with
comorbid
depression and
anxiety
482 controls
Placenta Exon 1F (and
partial
promoter 1F)
13 CpG sites
analyzed
Pyrosequencing No Prenatal stress
(mood disorder
during
pregnancy)
Maternal depression
during pregnancy was
associated with
newborn’s 1F
CpG-speciﬁc
hypermethylation,
which correlated to
several
neurobehavioral
variables.
Anxiety during
pregnancy was
associated with
newborn’s 11ˇ-HSD-2
speciﬁc CpG site
methylation, which
correlated with
newborn hypotonia.
<5% –
Steiger et al.
(2013)
n = 96
32 BN women
with childhood
abuse
32 BN women
without
childhood abuse
32 controls
Within BN
sample: 14
subjects with
comorbid BPD
and 14 subjects
with history of
suicidality
Peripheral
blood (whole
blood)
Promoters 1B,
1F, 1C and 1H
195 CpG sites
analyzed
Sequenom
EpiTYPER
platform
(MALDI-TOF
mass
spectrometry)
No Childhood
adversity
(Childhood
Trauma
Interview)
BN subjects with
comorbid BPD showed
higher methylation at
speciﬁc CpG sites of 1C
promoter and lower
methylation at 1H
promoter.
BN subjects with
previous history of
suicidality showed
elevated methylation
at speciﬁc CpG sites of
1C promoter.
<5% –
Labonté et al.
(2014)
n = 43
27 PTSD subjects
16 never
exposed to
trauma controls
Peripheral
blood (T
lymphocytes)
Promoters 1B
and 1C
83 CpG sites
analyzed
Sequenom
EpiTYPER
platform
(MALDI-TOF
mass
spectrometry)
Yes Childhood and
adulthood
adversity (an
index of
traumatic
events)
PTSD subjects showed
higher 1B and 1C
expression together
with lower
methylation.
<5% (overall
percentage
across the
region)
PTSD subjects
showed lower
levels of basal
cortisol
correlating
with 1B
methylation
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Table 1 (Continued )
Study Sample
size/characterization
Tissue Analyzed CpG
sites
Methylation
assessment
Expression Stress measure Epigenetic ﬁndings Extent of the
reported
methylation
differences
Correlated
biomarkers
(i.a., cortisol
measurements)
Weder et al.
(2014)
n = 190
94 maltreated
children
96 controls
Saliva 41 CpG sites
distributed all
across
alternate
non-coding
NR3C1 exons
Illumina 450K
Methylation
BeadChip
No Childhood
adversity (child
protective
services
reports; CTQ;
mother reports
of domestic
violence)
Maltreated children
showed differential
CpG-speciﬁc
methylation at the
NR3C1 locus.
FKBP5 methylation was
also associated to
maltreatment.
NA Speciﬁc CpG
site
methylation
predicted
morning
cortisol values
Yehuda et al.
(2014)
n = 122
61 PTSD subjects
61 controls
Peripheral
blood (PBMC)
Promoter 1F
39 CpG sites
analyzed
Sodium
bisulﬁte
mapping,
cloning and
sequencing
No Childhood
adversity (Early
Trauma
Inventory)
PTSD subjects showed
lower methylation.
Promoter 1F
methylation negatively
correlated to clinical
severity.
<5% PTSD subjects
showed greater
GR sensitivity;
methylation
negatively
correlated with
cortisol decline
Perroud et al.
(2014)
n = 50
mother-child
dyads
25 widows
pregnant during
the Rwanda
genocide
25 controls
Peripheral
blood
(leukocytes)
Exon 1F
10 CpG sites
analyzed
Pyrosequencing Yes Prenatal stress
(maternal
exposure to
genocide
during
pregnancy)
Exposed mothers and
their children showed
higher 1F methylation
and lower GR levels.
Methylation negatively
correlated to
expression.
<15% Exposed
mothers and
their children
exhibited
lower basal
cortisol levels
Van der Knaap
et al. (2014)
n = 468
adolescents
informative for
perinatal stress
and stressful life
events
experienced
either in
childhood or
adolescence
Peripheral
blood (whole
blood)
Promoters 1D,
1F and 1H
108 CpG sites
analyzed
Sequenom
EpiTYPER
platform
(MALDI-TOF
mass
spectrometry)
No Prenatal stress
(preterm
delivery, low
birth weight,
maternal
alcohol use or
smoking during
pregnancy,
etc.);
Childhood
adversity (a list
of stressful life
events
experienced
between the
ages 0 and 15
years; the
number of
traumatic
youth
experiences
before the age
of  16)
Exposure to stress
either in childhood or
adolescence was
associated with higher
methylation in 1F and
1H regions.
NA –
H
.
 Palm
a-G
udiel
 et
 al.
 /
 N
euroscience
 and
 Biobehavioral
 R
eview
s
 55
 (2015)
 520–535
 
527
Stroud et al.
(2014)
n = 100
mother-child
dyads
53 smokers
during
pregnancy
Placenta Exon 1F (and
partial
promoter 1F)
13 CpG sites
analyzed
Pyrosequencing No Prenatal stress
(maternal
smoking during
pregnancy) and
newborn stress
reactivity
(NNNS)
Maternal smoking
during pregnancy
negatively correlated
with newborn 1F
speciﬁc CpG site
methylation.
<5% Maternal
smoking during
pregnancy was
associated with
attenuated
baseline
cortisol and
cortisol
reactivity over
the ﬁrst
postnatal
month
Martín-Blanco
et al. (2014)
n = 281 BPD
subjects
Peripheral
blood
(leukocytes)
Exon 1F
8 CpG sites
analyzed
Pyrosequencing No Childhood
adversity (CTQ)
1F exon methylation
correlated with both
childhood
maltreatment and
clinical severity.
NA –
Romens et al.
(2014)
n = 56 children
18 physically
maltreated
children
38 controls
Peripheral
blood (whole
blood)
Exon 1F (and
partial
promoter 1F)
13 CpG sites
analyzed
Pyrosequencing No Childhood
adversity
(records
reporting
childhood
physical
maltreatment)
History of
maltreatment
correlated with
methylation at speciﬁc
CpG sites of exon 1F.
<10% –
Vukojevic et al.
(2014)
n = 152 survivors
from the 1994
Rwandan
genocide
93 PTSD subjects
59 controls
Saliva Exon 1F
8 CpG sites
analyzed
Pyrosequencing Yes Childhood and
adolescent
adversity
(checklist of 36
traumatic
event types)
1F CpG-speciﬁc
methylation negatively
correlated to both
symptom severity and
GR expression (in
saliva).
NA Speciﬁc CpG
site
methylation
correlated with
brain activity
and memory
performance,
only in men
Abbreviations:  BN, bulimia nervosa; BPD, borderline personality disorder; CTQ, childhood trauma questionnaire; EPD, early parental death; IPV, intimate partner violence; MDD, major depressive disorder; NA, non-available;
NNNS,  NICU network neurobehavioral scale; PBMC, peripheral blood mononuclear cell; PRAQ, pregnancy related anxiety questionnaire; PTSD, post-traumatic stress disorder; TSST, Trier social stress yest.
Extended results and further discussion can be found in Section 3.
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esearch. Additionally, there is a number of scales designed for char-
cterize speciﬁc disorders and/or target populations, which have
een utilized in the studies analyzed in this review such as: (i) Edin-
urgh Depression Scale (EDS); (ii) Hamilton rating scale for anxiety
HAM-A); (iii) Hamilton rating scale for depression (HAM-D); and
iv) Pregnancy Related Anxiety Questionnaire (PRAQ).
Early life stress (ELS) can be also measured by a number of scales.
he Childhood Trauma Questionnaire (CTQ) is a validated instru-
ent commonly used for research purposes which measures ﬁve
ypes of childhood adversity: physical, sexual and emotional abuse
nd physical and emotional neglect. Papers reviewed include sev-
ral measures of early adversity such as the Childhood Trauma
nterview (CTI), the Early Trauma Inventory – Self Report (ETI-SR)
nd the Childhood Experience of Care and Abuse (CECA), among
thers.
Prenatal stress measures can be derived from Obstetrical Com-
lications (OCs). None of the articles reviewed herein included a
omprehensive examination of OCs but of speciﬁc maternal con-
itions that may  be deleterious for fetal growth and adequate
evelopment such as mood disorders experienced during preg-
ancy and pre-eclampsia.
Finally, stress reactivity can be quantiﬁed by means of several
hallenges such as: (i) the Trier Social Stress Test (TSST), where
ortisol levels are monitored in subjects exposed to psychosocially
tressful situations; (ii) the dexamethasone suppression test (DST),
here subjects are administered with a synthetic glucocorticoid,
examethasone, in order to measure HPA axis functioning; and (iii)
he combined dexamethasone/CRH (dex/CRH) challenge, where
ollowing dexamethasone administration, subjects also receive a
RH dose for a more sensitive measure of HPA axis activity.
.3. NR3C1 gene and CpG island structure
The NR3C1 gene codes for the glucocorticoid receptor and is
ocated in the reverse strand of chromosome 5q31. It has 16 splice
ariants, 3 isoforms which are derived from 3′ splicing (GR-, GR-
 and GR-P) and 8 coding exons plus 9 alternate non-coding ﬁrst
xons which can be transcribed to the mRNA level but are not
ranslated to any known protein. The ﬁrst exons have different
xpression ratios along with distinct tissue distributions and their
unction remains widely unknown. In the 5′ untranslated region
f the NR3C1 gene, there is a CpG island spanning 3 kb located
t chr5:142,782,071–142,785,071 (GRCh17/hg19 assembly) which
ncludes seven of the aforementioned nine ﬁrst exons: 1D, 1J, 1E,
B, 1F, 1C (which has three splice variants) and 1H. A schematic
iew of NR3C1 gene structure can be seen in Fig. 1. In addition, a
etailed view of the whole sequence of this CpG island is depicted
n Fig. 2, where all of its individual CpG sites have been highlighted.
GFI-A binding sites within exon 1F promoter are emphasized with
ed boxes as they constitute the main reported ﬁndings across the
iterature in both humans and rats.
. Results and discussion
.1. Variables assessed by papers reviewed
Table 1 summarizes the sample description, tissues analyzed,
ethodology used to assess DNA methylation, targeted regions
f the NR3C1 gene and stress variables considered in the 23
apers eligible for this review, along with their main ﬁndings.
1 papers analyzed some sort of ELS: 8 of them focused on pre-
atal stress, 12 examined childhood and/or adolescent trauma,
hile one additional paper took into account both prenatal stress
nd childhood adversity. Thirteen of the studies were performed
n healthy subjects, while the remaining ten examined severalehavioral Reviews 55 (2015) 520–535
psychiatric disorders including major depressive disorder (MDD),
post-traumatic stress disorder (PTSD), borderline personality dis-
order (BPD), bulimia nervosa (BN) and suicide completion (SC). The
samples analyzed included post-mortem brain tissue (n = 2), saliva
(n = 4), cord blood and placenta (n = 7) and peripheral blood (n = 10),
while one of the studies speciﬁcally examined T cells.
3.2. NR3C1 methylation, ELS and psychopathological condition
Seventeen of the 21 papers accounting for ELS found signiﬁcant
correlations between ELS exposure and DNA methylation at a num-
ber of CpG sites located at several of the alternate ﬁrst exons of the
NR3C1 gene. The ﬁndings are reported below, sorted by region. The
paradigmatic region encompassing exon and promoter 1F will be
the ﬁrst to be reviewed.
3.2.1. NR3C1 gene – 1F region
The region 1F (including both promoter and exon) contains 47
CpG sites; 25 of them have been reported at least once as being
differentially methylated. Although nearly all the research groups
(20 out of 23) considered methylation of the NR3C1 region 1F, not
all of them analyzed the same section (Table 2). As shown in Fig. 3,
most researchers included the region immediately anterior to exon
1F in their analyses; this genomic locus is particularly intriguing
since it contains the NGFI-A binding region which was  reported to
be epigenetically modiﬁed by Weaver et al. (2004). Accordingly,
methylation of this promoter region (comprising CpG sites from 35
to 37) has regularly been associated with both ELS and psychopath-
ological condition.
3.2.1.1. 1F region – CpG 35. CpG site 35 (also referred to as 1F
CpG 1 or F13 depending on the study) has been reported to be
differentially methylated by ﬁve research groups in association
with several phenotypes: (i) prenatal stress as measured by mater-
nal anxious-depressed condition during pregnancy (Hompes et al.,
2013; Oberlander et al., 2008); (ii) early parental loss and low lev-
els of parental care (Melas et al., 2013; Tyrka et al., 2012); and (iii)
childhood maltreatment (Weder et al., 2014). Hypermethylation
was always associated with early stress exposure, with the excep-
tion of the results of Weder et al., who did not report the direction
of the effect.
3.2.1.2. 1F region – CpG 36. 1F CpG 36 (also referred to as 1F CpG 2 or
F12) newborn hypermethylation has been associated with mater-
nal psychopathology during pregnancy in three separate studies,
as assessed by clinical records of depression diagnosis, EDS, HAM-
A, HAM-D and PRAQ fear of delivery and fear of integrity scores
(Conradt et al., 2013; Hompes et al., 2013; Oberlander et al., 2008).
3.2.1.3. 1F region – CpG 37. 1F CpG 37 (also referred to as 1F CpG
3 or F11) methylation has been associated with both ELS and
psychopathology in humans by six distinct research groups. It cor-
responds to the paradigmatic CpG dinucleotide reported by Weaver
et al. (2004) to be strikingly hypomethylated in rats which received
higher maternal care as pups. Increased 1F CpG 37 newborn meth-
ylation has been associated with maternal EDS and HAM-D scores
during pregnancy (Oberlander et al., 2008). Similarly, early parental
loss and childhood maltreatment were associated with hypermeth-
ylation at this CpG site in healthy adults (Romens et al., 2014;
Tyrka et al., 2012). Finally, 1F CpG 37 methylation was  found to
be decreased in PTSD subjects who  exhibited higher severity of
intrusive memories (Vukojevic et al., 2014), and in newborns either
formerly exposed to maternal smoking during pregnancy (Stroud
et al., 2014) or to a maternal anxious-depressed condition during
pregnancy, as measured by EDS and PRAQ fear of integrity scores
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Table  2
Main epigenetic ﬁndings in the region 1F.
Region 1F Main ﬁndings
1–29 Isolated associations between methylation at particular CpG sites and early psychosocial stress (see Table S3 for further detail).
30–32 Putative NGFI-A binding region. Increased methylation at this region was  associated with both prenatal stress and childhood abuse in three
independent studies. One additional study reported decreased methylation in association with prenatal stress (see Table S1 for further detail).
33–34  Methylation at CpG sites 33 and 34 was  not reported as associated with any stress or clinical variable in any of the papers reviewed.
35–38  NGFI-A binding region. CpG site 37 is homologous to rat’s CpG site 16 as identiﬁed by Weaver et al. (2004) to be differentially methylated
according to maternal behavior. Methylation at CpG sites 35–37 positively correlates to early stress exposure, as reported by six independent
research groups. One additional study reported this association to be negative when analyzing a CpG unit which included CpG sites 37 and 38.
Methylation negatively correlated to PTSD severity.
39–47 Methylation at this region positively correlates to early stress exposure as experienced either prenatally or during childhood. Altered
methylation at CpG sites 40–47 has been reported in BPD samples (see Table S2 for further detail).
Fig. 3. CpG site distribution among exon and promoter 1F. Template coded boxes correspond to regions analyzed, depending on research group. Some authors focused on
the  region immediately anterior to the 1F exon (Radtke et al., 2011; Vukojevic et al., 2014), others centered on the exon itself and even posterior sections (Martín-Blanco
et  al., 2014; Perroud et al., 2014, 2011), a major group of authors took into account both regions (Conradt et al., 2013; Oberlander et al., 2008; Romens et al., 2014; Stroud
et  al., 2014; Tyrka et al., 2012), and still another group took into consideration a major region spanning the 1F exon promoter (Edelman et al., 2012; McGowan et al., 2009;
Mulligan et al., 2012; Van der Knaap et al., 2014; Yehuda et al., 2014) or the whole subdivision of the CpG island including all of the regions cited above (Hompes et al.,
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ﬁ013;  Melas et al., 2013; Steiger et al., 2013). Both papers assessing methylation by
F promoter and exon: cg18068240, cg15645634, cg15910486, cg04111177 and c
espectively (Hogg et al., 2013; Weder et al., 2014).
Hompes et al., 2013). CpG 37 methylation will be discussed below
n association with secondary variables.
Remarkably, the results reported by Hompes et al. (2013) refer
o the CpG units F12.13 and F10.11, which include CpG sites 35 and
6, and CpG sites 37 and 38, respectively.
.2.1.4. 1F region – CpG sites from 30 to 32. A second cluster of dif-
erentially methylated CpG sites consists of the CpG dinucleotides
rom 30 to 32 which are located at a putative non-canonical NGFI-A
inding site (McGowan et al., 2009). Findings in this region are not
lways reported as CpG-speciﬁc but map  to a small cluster of CpG
inucleotides (Table S1). Three out of four papers found higher lev-
ls of methylation in this region associated with either childhood
buse or prenatal stress.
.2.1.5. 1F region – CpG sites from 39 to 47. Thirdly, a region
panning CpG sites 39–47, which are located in the exonic 1F
equence and beyond (toward the 1C promoter), has also been
idely reported as associated with several early stressor and psy-
hopathological outcomes by a number of authors (Table S2). Two
eparate groups found associations between average methylation
nd either childhood maltreatment (Perroud et al., 2011) or clini-
al severity (Martín-Blanco et al., 2014) in BPD samples in a region
ncompassing 1F CpG sites 40–47. One study reported signiﬁcantly
igher methylation percentages in a region spanning 1F CpG sites
0–39 (Radtke et al., 2011). Tyrka et al. (2012) found a high inter-
orrelation between methylation at CpG sites from 41 to 47; that
s to say, methylation at these CpG sites ﬂuctuate in a coordinated
ashion.
.2.1.6. Prior 1F regions – CpG sites 1–29. CpG-speciﬁc methylation
ndings in the region spanning CpG sites 1–29 are scarce (Table S3).ns of the Illumina 450K BeadChip included data on 5 isolated CpG sites within the
0381, which correspond to CpG sites 9, 35, 38, 39 and 41 (as numbered in Fig. 2)
Globally, increased methylation has been associated with several
measures of early stress (Hompes et al., 2013; Van der Knaap et al.,
2014).
Intriguingly, Edelman et al. found CpG site 12 to be differen-
tially methylated in males and females; while its methylation was
a signiﬁcant predictor of cortisol output after the Trier Social Stress
Test (TSST) only in females (Table 3), as discussed below in Sec-
tion 3.4. These results may  point to gender-speciﬁc regulation of
the HPA axis driven by subtle epigenetic differences in the NR3C1
gene. Accordingly, males and females respond very differently to
a stress challenge (Edelman et al., 2012). Differential modulation
of the stress response in males and females may be involved in
the large dependence of the prevalence of psychiatric illnesses on
gender.
PTSD continues to be associated with hypomethylation (Yehuda
et al., 2014). CpG sites 12 and 13 are of special interest since they
constitute a non-canonical NGFI-A binding site (McGowan et al.,
2009).
3.2.1.7. Mean methylation of other 1F subregions. Speciﬁc CpG data
were not available in four papers that assessed 1F methylation
(Edelman et al., 2012; Mulligan et al., 2012; Radtke et al., 2011;
Van der Knaap et al., 2014): the experience of ELS—such as mater-
nal exposure to intimate partner violence (Radtke et al., 2011),
war stress (Mulligan et al., 2012) during pregnancy or childhood
experiences of sexual abuse (Van der Knaap et al., 2014)—was asso-
ciated with average hypermethylation of 1F regions (see Fig. 3
for a detailed description of assayed 1F regions by paper). Fur-
thermore, Perroud et al. (2011) performed most of their statistical
analysis in relation to the mean methylation value and found asso-
ciations between 1F hypermethylation and both the severity and
frequency of different types of childhood maltreatment (specially
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Table  3
Correlations between peripheral cortisol measurements in either basal or stress-related conditions and NR3C1 methylation.
Study Methodology Findings
Oberlander et al.
(2008)
Saliva samples were collected at baseline and at post
stress recovery following a stress challenge
Greater methylation at 1F CpG 37 associates with greater HPA
reactivity (increasing cortisol after the stress challenge)
De Rooij et al. (2012)a Saliva samples were collected at 5 and 20 min  during
baseline, and in ﬁve occasions following several steps
of a psychological stress protocol
1C exon methylation was  positively associated with stress
reactivity cortisol levels (peak) and self-perceived stress
variables: perceived performance and control. It was  negatively
associated with perceived stress.
Tyrka et al. (2012) Dex/CRH test: following administration of
dexamethasone and CRH, blood samples were
collected at several time points for cortisol
determination
Cortisol concentration negatively correlated to methylation at 1F
CpG sites 36, 39 and the mean of CpG sites 41–47
Edelman et al. (2012) Trier Social Stress Test (TSST): salivary cortisol was
sampled 8 times (twice before the test and six times
after the stress task)
Only for women, average methylation of 1F promoter (CpG sites
1–39) negatively correlated to salivary cortisol after the TSST
Labonté et al. (2014) Basal cortisol levels were measured across daytime Cortisol levels were lower in the PTSD group, and 1B
CpG-speciﬁc methylation positively correlated to cortisol levels
Weder et al., 2014 Basal cortisol levels were measured in the morning CpG sites 1F 39 and 1C 11 predicted morning cortisol value
Yehuda et al. (2014) DEX Suppression Test (DST) and 24-h urine collection PTSD subjects exhibited a hypersuppression after DST together
with lower urinary cortisol excretion; 1F methylation negatively
correlated to cortisol decline
Perroud et al. (2014) Basal cortisol levels were measured in the morning Exposed mothers and their children exhibited lower cortisol
levels; 1F methylation negatively correlated to cortisol levels
Stroud et al. (2014) Cortisol stress response was  elicited using the NICU
Network Neurobehavioral Scale (NNNS)
MSDP-exposed children exhibited attenuated baseline cortisol
and cortisol reactivity together with 1F CpG 37 decreased
methylation
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exual abuse and physical neglect). Additionally, Yehuda et al.
2014) reported mean hypomethylation of 1F promoter in PTSD
ubjects. In contrast to the ﬁndings reviewed above, Steiger et al.
2013) found no associations between 1F methylation and either
PD, history of suicidality or childhood abuse.
.2.2. NR3C1 gene – 1B region
Two of the four studies that examined region 1B methylation
ound no association with prenatal stress (Hompes et al., 2013)
r either childhood abuse or clinical severity (Steiger et al., 2013).
ntriguingly, both the papers that did report associations between
sychopathology (either suicide completion or PTSD) and DNA
ethylation were authored by Labonté et al. (2014, 2012) and cover
 gene region placed immediately before exon 1E, including its
utative promoter and the whole exon 1J. Labonté et al. (2014)
howed a clear association between PTSD and overall hypomethyl-
tion of the 1B promoter region. In contrast, when studying suicide
ompleters with and without a history of childhood abuse, results
re not so straightforward. Suicide completers exhibited CpG-
peciﬁc hypermethylation at two CpG sites (one of them was found
o be associated with decreased GR expression) and hypomethyla-
ion at a third CpG site when compared to controls, independently
f history of childhood abuse (Labonté et al., 2012). The CpG sites
eported by the two studies do not match; even though exon 1B
s one of the most studied exons, there is no replication among
tudies.
.2.3. NR3C1 gene – 1C region
Three of the four studies speciﬁcally examining promoter and
egion 1C methylation were performed by the same research group
Labonté et al., 2014, 2012; Steiger et al., 2013) and cover sim-
lar regions encompassing 59 CpG sites; 11 of them have been
eported to be individually associated with either stress or psychi-
tric variables. Additionally, a second research group (De Rooij et al.,
012) analyzed a region speciﬁcally spanning exon 1C (exclud-
ng its promoter region from the analysis). Steiger et al. (2013)
ound no epigenetic correlates of experiencing childhood abuse in
N subjects with or without BPD. Nevertheless, they did observectivity suggesting that these variables may  be driving methylation differences or
a set of differential CpG-speciﬁc hypermethylation patterns in
both BN-BPD subjects when compared to controls without eat-
ing disorders, and in BN individuals with a history of suicidality
when compared to controls. Labonté et al. (2012) identiﬁed four
differentially methylated CpG sites in a suicide sample: one hyper-
methylated CpG site and one hypomethylated CpG site in suicide
completers with a history of childhood abuse when compared to
controls and non-abused suicide completers; and two hypermethy-
lated CpG sites in suicide completers when compared to controls
independently of history of childhood abuse. When examining
PTSD subjects, signiﬁcant global hypomethylation was revealed
in a region encompassing 54 CpG sites in the exon 1C promoter.
Remarkably, one speciﬁc CpG site was found hypermethylated in
PTSD patients (Labonté et al., 2014). Among healthy individuals,
De Rooij et al. (2012) described a positive association between 1C
mean methylation and levels of both education and physical activ-
ity; whereas methylation in this region negatively correlated to
smoking. Additionally, a ﬁfth study reported differential methyl-
ation at a speciﬁc CpG site (cg11152298) to be associated with
childhood maltreatment. Nevertheless, this study did not report
the direction of the effect and it is unknown whether early trauma
is associated with hypermethylation or hypomethylation (Weder
et al., 2014). Once again, there is no replication among studies of
region 1C differential methylation.
3.2.4. NR3C1 gene – 1H region
Two of the studies that examined exon 1H methylation ana-
lyzed a total of 69 CpG sites with a little overlap: just 6 CpG sites
were examined by both. They reported mean hypomethylation val-
ues in either suicide completers with a history of childhood abuse
(Labonté et al., 2012) or BN-BPD individuals (Steiger et al., 2013)
compared to controls. Nevertheless, a third study extended the
region analyzed beyond exon 1H and reported higher methylation
values in association with several measures of early trauma, such
as repeated exposure to sexual and physical abuse or stressful life
events experienced during adolescence (Van der Knaap et al., 2014).
The different methods used in prior studies preclude the replication
of results.
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.2.5. NR3C1 gene – 1D region
Hompes et al. (2013) found signiﬁcant correlations between
everal measures of prenatal stress and levels of methylation at
0 CpG sites in exon 1D (pertaining to 4 methylation units iden-
iﬁed by MALDI-TOF) as measured in cord blood from newborns.
dditionally, Van der Knaap et al. (2014) observed a signiﬁcant
egative correlation between repeated exposure to “other trauma”
non-sexual and non-physical) and overall methylation of a region
panning exon 1D and beyond. Furthermore, Hogg et al. (2013)
etected signiﬁcant associations between methylation at CpG sites
g21702128, cg14558428, cg24026230 and cg13648501—which
re located in the 1D promoter—and early-onset pre-eclampsia
EOPE), together with higher mean methylation values at exon 1D
n EOPE subjects compared to controls. Lastly, Weder et al. (2014)
lso found differential methylation at CpG sites cg21702128 and
g13648501 in association with childhood maltreatment. Never-
heless, these associations lack the direction of the effect and it is
nknown whether early trauma is associated with hypermethyl-
tion or hypomethylation. In this case, the 1D CpG dinucleotides
ncluded in the Illumina BeadChip do not match those assessed by
ompes et al. or van der Knaap et al., which contributes to the lack
f replicated results (the equivalence of the Illumina nomencla-
ure and the CpG site numbering adopted in the current review is
isplayed in Table S4).
.3. NR3C1 promoter methylation inversely correlates with GR
xpression
Six of the 23 papers reviewed explored GR expression coupled
ith epigenetic analysis (Hogg et al., 2013; Labonté et al., 2014,
012; McGowan et al., 2009; Perroud et al., 2014; Vukojevic et al.,
014). Five of them described negative correlations between NR3C1
ethylation at different ﬁrst exons (including CpG sites in the 1B,
C and 1F exons) and GR expression (either total GR mRNA or
peciﬁc GR transcripts) in both brain and peripheral tissues (T lym-
hocytes and saliva). Intriguingly, Labonté et al. (2012) reported a
ositive rather than negative association between 1H methylation
nd expression which draws our attention back to Section 3.2.4,
ince 1H methylation values were the only ones to be negatively
ssociated with early stress.
Conversely, Hogg et al. (2013) did not ﬁnd any relationship
etween NR3C1 methylation and expression. However, they did
ot assay 1D containing transcripts but generic NR3C1 expres-
ion, which may  have diluted moderate methylation changes of a
carcely expressed transcript. Nevertheless, there is no data on the
xpression of GR transcripts containing the 1F exon in peripheral
lood in relation to 1F methylation.
.4. NR3C1 methylation and stress reactivity
Nine of the 23 papers reviewed measured cortisol levels either
t baseline or after a stress challenge—such as the Trier Social
tress Test (TSST) or the Dex/CRH challenge—in order to measure
asal and stress-related HPA axis functioning. These studies pro-
uced inconsistent data (Table 3). While ﬁve papers point to a
ositive association between methylation and cortisol levels, either
t baseline or after a stress challenge (De Rooij et al., 2012; Labonté
t al., 2014; Oberlander et al., 2008; Stroud et al., 2014; Yehuda
t al., 2014), three studies claim these associations to be nega-
ive (Edelman et al., 2012; Perroud et al., 2014; Tyrka et al., 2012).
urthermore, methylation at two CpG sites as analyzed by Weder
t al. (2014) were found to predict morning cortisol values but
he direction of the effect is not reported. Controversial ﬁndings
egarding cortisol measurements are in line with previous studies
for a review, see Strüber et al., 2014).ehavioral Reviews 55 (2015) 520–535 531
3.5. Both hypermethylation and hypomethylation of the NR3C1
gene may  be maladaptive
While hypermethylation at speciﬁc CpG sites has been linked to
ELS (see Section 3.2), a global pattern of hypomethylation has been
found in PTSD subjects. Intriguingly, depressed patients are widely
reported to show non-suppression after the dex/CRH test (Heim
et al., 2008); while individuals suffering from PTSD exhibit a hyper-
suppression after the DST (McFarlane et al., 2011). This divergence
suggests that the timing of the stress exposure could determine
differential modulations of HPA axis functioning: (i) early adver-
sity, such as prenatal stress or childhood maltreatment, increases
methylation in promoter regions of the NR3C1 gene which dampens
GR expression, promotes glucocorticoid resistance and may  trigger
several psychiatric disorders, such as a depressive episode or BPD
in adulthood; (ii) late and acute exposure to trauma may  induce
demethylation in the same regions, thus increasing GR expression
and leading to a sensitization of the HPA axis.
Alternatively, subjects with hypomethylation of the NR3C1 gene
prior to trauma may  suffer stress coping difﬁculties together with
an increased recall of negative memories, thus becoming more sus-
ceptible to developing PTSD after being exposed to severe trauma
during adulthood. In fact, Perroud et al. (2014) recently reported
the percentage of methylation of the NR3C1 exon 1F across a
sample of genocide-exposed mothers and their children, thus pro-
viding methylation measures that can be associated with late stress.
Intriguingly, the exposed mothers showed increased CpG-speciﬁc
methylation compared to non-exposed mothers, which suggests
stress-associated NR3C1 hypermethylation at any stage of life and
further supports a role of basal hypomethylation prior to trauma in
triggering PTSD.
3.6. Biological relevance of methylation at a NGFI-A binding site
Intriguingly, four papers reported separate biomarker-like fea-
tures associated with exon 1F CpG 37 methylation. As discussed
in Section 3.4, Oberlander et al. (2008) reported an association
between methylation at this particular CpG site and HPA axis
responsiveness: infants with increased cortisol responses after a
stress challenge had higher methylation. Meanwhile, Stroud et al.
(2014) found CpG 37 methylation to be positively correlated with
cortisol reactivity. Accordingly, Yehuda et al. (2014) found the same
association in PTSD subjects whose CpG 37 methylation was  lower
and predicted cortisol levels after the DST. Subsequently, Vukojevic
et al. (2014) investigated the putative interaction between NR3C1
methylation and memory performance during a fMRI picture-
recognition task in healthy subjects; they found a correlation
between CpG 37 methylation and brain activity related to the suc-
cessful recognition of previously seen pictures in men but not in
women. Strikingly, CpG 37 methylation was  negatively correlated
with the correct recognition of previously seen pictures in men.
3.7. Tissue distribution of alternative non-coding ﬁrst exons
The tissue distribution of GR ﬁrst exons has been extensively
examined. In this regard, mRNA containing exons 1B or 1C in
any of its splice variants (1C1–1C3) constitute the most widely
expressed NR3C1 transcripts as they are detected in the hippocam-
pus, T cells, B cells, monocytes, heart muscle, lungs, liver and skin,
among other tissues examined (Presul et al., 2007; Turner and
Muller, 2005). Moreover, mRNAs containing either 1B or 1C are the
most abundant transcripts in several brain areas including the hip-
pocampus (Alt et al., 2010). In contrast, exons 1E and 1J are the least
abundant in brain, with marginal expression ratios accounting for
0.1% of total GR expression (Alt et al., 2010). Strikingly, intronic
upstream regions preceding both the 1E and 1J exons do not exhibit
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romoter activity as opposed to the corresponding regions of the
ve remaining ﬁrst exons located in the same CpG island (Cao-Lei
t al., 2011). Exons 1D, 1F and 1H exhibit intermediate expression
atios. Exon 1D has been reported to be expressed in brain and pla-
enta (Hogg et al., 2013); exon 1F is expressed in immune cells
nd brain (Turner and Muller, 2005); and exon 1H has been found
o be expressed in several tissues including liver, lung, heart mus-
le and a number of blood cell subpopulations (Turner and Muller,
005). Interestingly, the human hippocampus was the only tissue
nalyzed where all the non-coding exons are present at the mRNA
evel (Turner and Muller, 2005).
. Conclusions
This study is the ﬁrst to systematically review all the scien-
iﬁc literature regarding NR3C1 non-coding ﬁrst exon methylation
n association with both psychosocial stress at several stages of
ife (including fetal development, early childhood, adolescence and
dulthood) and a broad range of stress-related disorders. Even
hen accounting for moderate differences, early life adversity has
een repeatedly shown to be associated with hypermethylation at
everal CpG sites located in the non-coding ﬁrst exons of the NR3C1
ene. Such epigenetic modiﬁcations may  impair HPA axis function-
ng and further predispose early stress-exposed subjects to a wide
ange of psychiatric conditions, such as major depression or bor-
erline personality disorder, in adulthood. Taking into account all
he ﬁndings discussed in this review, some methodological issues
hould be noted for further research (as summarized in Fig. 4).
.1. How do we assess DNA methylation?
Our ﬁrst concern regard the differences observed in the assess-
ent of methylation across the various studies, which preclude
eta-analysis. On the one hand, the methods used to measure
ethylation differed greatly between studies including: bisulﬁte
yrosequencing; cloning and further Sanger sequencing of regions
f interest; the use of genome-wide methylation arrays; and mass
pectrometry (MS) analyses. Because of the limited capacity of MS
o discriminate between speciﬁc CpG dinucleotides, studies using
ALDI-TOF tend to report average methylation values in minor sets
panning two or more individual CpG sites, rather than CpG-speciﬁc
esults (Hompes et al., 2013; Melas et al., 2013; Van der Knaap et al.,
014). This methodological discrepancy could be the primary cause
f the apparently controversial ﬁndings of two separate research
roups focusing on the same 1F region while analyzing almost
dentical prenatal stress variables (Hompes et al., 2013; Oberlander
t al., 2008); as discussed in Section 3.2.1. Their opposing ﬁndings
lso correspond to different stages of pregnancy, which may  have
ontributed to the heterogeneity of the results. However, the results
eported by Hompes et al. correspond to a CpG unit including CpG
ites 37 and 38; thus, CpG 37 methylation could be masked by a
arked hypomethylation of CpG 38.
On the other hand, regardless of the method selected, while
ome authors reported average methylation of assayed regions,
thers displayed their data in a CpG by CpG fashion, while a
hird group reported both measures of methylation. The authors
eporting both types of data reveal the seeming biological rel-
vance of assaying methylation in a CpG-speciﬁc manner. For
nstance, McGowan et al. (2009) detected a higher global methyl-
tion percentage in abused suicide victims than in either controls
r non-abused suicide victims. Strikingly, when examining individ-
al CpG sites, it seems that this overall difference is mainly driven
y two out of 38 assayed CpG sites (CpG sites 30 and 32). Thus,
ean methylation differences could be driven by a very few truly
nformative CpG sites placed in biologically relevant positions, suchehavioral Reviews 55 (2015) 520–535
as transcription factor binding sites, such as, the widely reported
nerve growth factor-inducible protein A (NGFI-A) binding site in
both rats (Weaver et al., 2004) and humans (McGowan et al., 2009).
However, once the speciﬁc methylation value is available, the
statistical approach is still challenging. There a number of con-
founders which may  directly inﬂuence methylation, mainly (i)
genetic variability in the DNA methylation machinery genes, and
(ii) genetic variability affecting the epigenetically regulated region
of interest. Genetic variability in epigenetic machinery genes has
been widely studied regarding psychiatric disorders (Murgatroyd
and Spengler, 2012) and genetic variation of a DNA methyl-
transferase (DNMT3B) has been associated with environmental
sensitivity affecting cognitive plasticity (Córdova-Palomera et al.,
2015). In this regard, genetic variation directly affecting CpG sites
will modify methylation percentage as these regions will be unable
to be chemically modiﬁed to incorporate a methyl group. Neverthe-
less, there are almost no described SNPs overlapping with CpG sites
of interest at the NR3C1 gene and, when present, they display very
low minor allele frequencies (such as rs562481368 or rs573565118,
both located at region 1F, overlapping with CpG sites 39 and 46
respectively).
4.2. Where do we look?
Secondly, there is no agreement regarding the delimitation of
NR3C1 ﬁrst exon promoter regions. This could be the reason why
authors who allegedly focus on the same exons have actually ana-
lyzed distinct CpG sites. This may  be due to late annotations of
exons 1D–1J compared to the initial report of exons 1A–1C, which
lead to several misconceptions regarding the topic. In fact, another
controversial issue is whether to explore promoter or exonic
regions; or both. Most of the papers reviewed rely on epigenetic
ﬁndings reported in rats (Weaver et al., 2004) and consequently
concentrate on human exon 1F and its associated promoter. Hence,
region 1F should be further analyzed as this exon may  be key for the
modulation of stress responses. Furthermore, some authors exam-
ined wider regions according to expression studies in brain tissue
(Alt et al., 2010). Exons 1B and 1C should be examined in detail
since they are the most expressed NR3C1 ﬁrst exons throughout the
body, including the brain. Intriguingly, ﬁndings reported for these
exons—although limited—seem to be associated with ﬁnal psycho-
pathological phenotype (either suicide completion or PTSD) rather
than with any early life stressor; which further suggests a possible
role as biomarkers.
Moreover, the region 1E emerges as an elusive target. Although
it has not been directly addressed by any research group, Labonté
et al. examined its putative promoter methylation, while theoret-
ically focusing on the 1B promoter. Recently, Cao-Lei et al. (2011)
examined all the intronic regions immediately upstream of exons
1B–1F plus 1H and 1J and reported promoter activity for all of them
except those preceding exons 1E and 1J. Further studies need to be
performed on the 1J/E region in order to determine whether epige-
netic modiﬁcations have the potential to modulate the expression
of the least abundant ﬁrst exons of the NR3C1 gene; and whether
such variations have any functional repercussion on GR activity and
further HPA dysregulation. As they are the least expressed exons,
they could promote the transcription of the least abundant isoform
of the glucocorticoid receptor: GR-, whose function and relevance
are still largely unknown, but which seems to antagonize GR-
thereby promoting glucocorticoid resistance (Turner et al., 2010;
Webster et al., 2001). Interestingly, transcripts containing exon
1E have been reported to be expressed in immune cells, partic-
ularly in monocytes and CD8+ T cells (Turner and Muller, 2005).
Indeed, a decreased GR/GR expression ratio has been identi-
ﬁed in monocytes from MDD  patients, which suggests a further
role of NR3C1 modulation in ongoing psychopathological status
H. Palma-Gudiel et al. / Neuroscience and Biobehavioral Reviews 55 (2015) 520–535 533
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Carvalho et al., 2014). There is much literature regarding the com-
lex interplay between the HPA axis and immune system, e.g., the
anus-faced actions of glucocorticoids on the modulation of inﬂam-
atory response (Sorrells et al., 2009), as well as the putative
ngagement of inﬂammation in the etiology of psychiatric disor-
ers (Haroon et al., 2012). Cortisol can act as an anti-inﬂammatory
olecule by means of peripheral GR located in immune cells, which
hould encourage future research to focus on the study of the epi-
enetic signature of exon 1E in peripheral samples, as it may be
nvolved in the neuroendocrine modulation of inﬂammation.
In addition, exons 1D and 1H need to be studied further since
he evidence regarding their association with early stress is very
imited. These exons reach transcription rates comparable to those
f exon 1F. Finally, a certain pool of CpG sites remains unexplored.
lthough they are placed within the CpG island containing exons
B–1F, 1H and 1J, they have not been targeted by any study to date
Fig. 4).
Furthermore, researchers in this ﬁeld do not only need to
hoose carefully which exons—and which CpG sites along with
hem—should be analyzed, but also in which tissues. As exempliﬁed
n several reviews but particularly in the current one, epigenetic
esearch has been conducted on a number of tissues including post-
ortem brain samples together with peripheral tissues such as
aliva and blood. Epigenetic signatures are known to differ from one
issue to another; nevertheless, recent studies encourage the com-
on  assumption of epigenetic hallmarks in blood being replicable
n brain tissues (Ewald et al., 2014; Masliah et al., 2013).
Finally, it is important to keep in mind that DNA methylation
oes not operate on its own but in conjunction with a number of
dditional epigenetic mechanisms such as histone modiﬁcation and
icroRNA-mediated gene silencing. While there is no research yet
egarding the role of histone modiﬁcations in NR3C1 regulation,
icroRNAs are gaining popularity and will be studied extensivelyn the next decade. As proposed by Turner et al. (2010) in a pre-
ious review, microRNAs may  play an essential role in regulating
ranslation of GR. Recently, several authors have suggested the role
f microRNAs in either the regulation of a GR-dependent signalingns to improve our knowledge of the role of early life stress upon NR3C1 methylation
s non-coding alternate ﬁrst exons 1D–1J spanning 3 kb. This CpG island consists of
network (Vallès et al., 2014) or the development of glucocorticoid
resistance after exposure to chronic stress (Jung et al., 2015). Inter-
estingly, it has been also described that expression of a speciﬁc
microRNA (miR-137, which is a hit of a GWAS for schizophrenia)
can be regulated by methylation in adult neural stem cells from
mice (Szulwach et al., 2010) thus illustrating the crosstalk between
distinct epigenetic marks in neural tissue.
4.3. Why  do we analyze NR3C1 methylation?
Identifying epigenetic signatures associated with early stress
or psychopathology does not imply causality. A limited number
of papers examine mRNA expression in relation to epigenetic
modiﬁcations (Hogg et al., 2013; Labonté et al., 2014, 2012;
McGowan et al., 2009; Perroud et al., 2014; Vukojevic et al., 2014).
Such research is essential in order to establish functional corre-
lations between methylation patterns and phenotypic variation.
The expression studies reviewed here were performed in either
brain tissue, saliva or blood samples. Notably, ﬁve of the six stud-
ies that assessed expression together with methylation reported
an inverse association between the aforementioned variables. Fur-
ther studies examining both DNA methylation and gene expression
are needed to elucidate the functional repercussions of epigenetic
modiﬁcations of the exon 1F in relation to ELS.
There is still a major concern regarding the extent of the
reported methylation differences (Table 1). DNA methylation is an
absolute modiﬁcation: a CpG site is either methylated or unmethy-
lated. Accordingly, methylation percentages ranging from 0% to
100% indicate uneven methylation across different cells. It is worth
noting that most of the reported signiﬁcant differences included
in this review are values either under 5% or merely not speciﬁed
(nor suitable to be extrapolated from ﬁgures). This may raise three
concerns: (i) between-group differences of 5% are certainly close
to the detection sensitivity limits of the methylation assessment
techniques employed (Klengel et al., 2014); (ii) these small changes
are likely to be caused by marginal cellular subsets (accounting
for a tiny fraction of the total cell population), which may have
5 d Biob
b
l
c
t
c
i
b
C
I
a
w
a
a
e
a
a
a
n
i
l
v
o
4
i
r
a
s
a
e
o
i
t
i
p
s
s
h
l
(
w
y
s
n
f
m
m
r
E
g
A
T
w
C
t
P
i34 H. Palma-Gudiel et al. / Neuroscience an
een differentially methylated after a stressor; and (iii) since the
ink between DNA methylation and gene expression is relatively
ontinuous (Siegfried and Simon, 2010), these minor methyla-
ion differences may  induce only relatively small transcriptional
hanges.
Nevertheless, several reports have consistently found this CpG
sland to be widely unmethylated with average methylation levels
elow 5% suggesting that small methylation increases in crucial
pG sites may  have the potential to inﬂuence transcription greatly.
n this regard, it is worth mentioning that some novel statistical
pproaches to analyze DNA methylation changes between groups,
ith a special emphasis on large methylation differences, have been
ble to retrieve biologically-feasible results (Dempster et al., 2014)
nd may  thus be useful in this context.
These moderate methylation differences could be due to differ-
ntial methylation patterns across distinct cell types. Both blood
nd brain samples comprise a number of separate cell types such
s monocytes, T-lymphocytes and B-lymphocytes, and neurons,
strocytes and microglia, respectively. Focusing on epigenetic sig-
atures of speciﬁc cell types rather than measuring methylation
n mixed tissues may  elucidate not only which genes are deregu-
ated in pathological conditions but also which cell types are more
ulnerable to stress and thus involved in the etiology of these dis-
rders.
.4. Future directions
All of the foregoing should be taken into account in future stud-
es that examine the methylation of the NR3C1 gene promoter
egion. Likewise, the exons to be studied should be selected in
ccordance with transcriptional studies, providing mRNA expres-
ion and tissue distribution data in order to focus on regions that
re biologically relevant for HPA axis functioning. In this regard,
xon 1F showed a signiﬁcantly lower expression in the hippocampi
f MDD  subjects than in controls; which suggests its involvement
n the etiology of mood disorders (Alt et al., 2010). Future selec-
ion of the CpG sites to be analyzed should prioritize those located
n transcription factor (TF) binding regions, since methylation can
revent TF binding and thus impair gene expression. Additionally,
peciﬁc cell types are more likely to exhibit homogenous epigenetic
ignatures rather than mixtures such as peripheral blood or brain
omogenate.
With regard to study design, it would be very informative to ana-
yze several variables simultaneously. Some such suggestions are:
i) to study both prenatal and childhood stress in order to assess
hether they have additive or synergistic effects on NR3C1 meth-
lation; (ii) to collect lifestyle information such as drug exposure,
moking habits and other factors known to modify epigenetic sig-
atures as they can confound the results; (iii) to assess immune
unction by means of cytokine determination in plasma, to deter-
ine the extent to which psychosocial stress-induced epigenetic
odiﬁcations of the NR3C1 gene can modulate the inﬂammatory
esponse; and (iv) to study monozygotic twins discordant for either
LS or psychopathology in order to rule out heterogeneity due to
enetic variability and non-shared environment.
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